Kashiv biosciences enters into exclusive licensing agreement with alvotech for development & commercialization of a proposed biosimilar to xolair® (omalizumab)

Piscataway, n.j. & reykjavik, iceland--(business wire)--kashiv biosciences llc (“kashiv”), a fully integrated biopharmaceutical company, and alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that they have entered into an exclusive licensing agreement for adl018 (also called avt23), a proposed biosimilar to xolair® (omalizumab), which is in clinical development. the agreement covers a.
ALVO Ratings Summary
ALVO Quant Ranking